Herpes Simplex Virus (HSV) is a common infection which may be transmitted between people who are asymptomatic or symptomatic with primary or recurrent infections. Infection can occur with HSV-1 and HSV-2.

In neonates HSV-2 causes 75% of infections and HSV-1 25%. HSV infection in newborns has an incidence of 1:3000 to 1:20000 depending on the geographical location. There is concern that with the increasing incidence of HSV-2 infection, numbers of newborn HSV infection will increase. The overall global rate of neonatal HSV is estimated to be 10 per 100,000 live births, with a best estimate of 14,000 cases annually.

Refer to the Women and Newborns Health Service guideline – Herpes Simplex in Pregnancy for information on antenatal management, antibody testing and delivery of HSV positive women.

Transmission

- Neonatal HSV is most commonly transmitted perinatally by passage through an infected genital tract or through an ascending infection. HSV can transmit through intact membranes.
- Risk factors for HSV transmission to neonate:
  1. Type of maternal infection [first-episode primary (57%) > first-episode non-primary (25%) > recurrent (<2%)]
  2. Maternal HSV serology status
  3. Mode of delivery (vaginal > C-section)
  4. Duration of rupture of membranes
  5. Disruption of cutaneous barrier (fetal scalp electrodes and other instrumentation)
  6. HSV serotype (HSV-1 > HSV-2)

The risk of transmission of HSV to the neonate remains significantly higher with primary maternal infections acquired closer to the time of delivery compared with recurrent infections (50–60% with primary infections vs <3% for recurrent infections). Distinguishing between primary and recurrent HSV infection in women by history and examination may be impossible. Maternal type specific serology may be useful.

- More than 75% of infants with HSV infection have been born to women with no history or clinical findings suggestive of active HSV infection during pregnancy.
- Congenital HSV infection may also occur, but is very rare.
Herpes Simplex Virus (HSV): management of neonates born to HSV positive women

- Rarely HSV is acquired through postnatal transmission from a parent or caregiver with oro-labial HSV or herpetic whitlow.
- Neonatal HSV can be acquired in-utero (5%), in the peripartum period (85%), or in the postnatal period (10%).

Clinical Manifestations

Most cases present within 60 days of life. In newborns, HSV can manifest as:

- **SEM disease** (≈45%): Disease localised to skin, eye and mucous membranes. 80% of infants present with vesicular rash and usually present at 10–12 days of life.

- **Central nervous system disease** (≈30%): Neonates usually present at 16–19 days of life, although can present within the first month of life. CNS disease presents with lethargy, irritability, tremors, poor feeding, temperature instability, full anterior fontanel and seizures.

- **Disseminated disease** (≈25%): Can involve multiple organ systems including liver, lungs, CNS, heart, adrenal glands, bone marrow, kidneys, gastrointestinal tract and SEM. Disseminated disease presents with viral sepsis, and may be indistinguishable from sepsis of another cause. It should be considered especially if neonate presents with respiratory/hepatic failure with disseminated intravascular coagulation (DIC). Disseminated disease presents early and usually around day 10-12 of life.

It is important to consider HSV infection in the differential diagnosis of all acutely unwell neonates, especially if there is a sepsis-like presentation and a maternal history of HSV. In up to 40% of newborns with HSV, there are no skin lesions. In the absence of skin lesions diagnosis may be delayed.

Diagnostic Tests

- Serology is of limited value, as IgG is of maternal origin.

- Surface swabs (transport in viral medium) for immunofluorescence, HSV culture and HSV PCR:
  - Skin vesicles if present.
  - Umbilical stump.
  - Mouth or nasopharynx.
  - Eyes (conjunctival swabs).
  - Rectum (rectal swab).
  - Urine.
  - Tracheal aspirate (if ventilated).
  - HSV PCR from blood. This requires 0.5 mL EDTA blood.
  - Lumbar puncture for HSV PCR: indicated in all cases, where clinically stable.
  - Other tests:FBC, Coagulation screen, Liver function tests.
  - Chest X-ray if respiratory symptoms.
Herpes Simplex Virus (HSV): management of neonates born to HSV positive women

Treatment

Aciclovir should be given whilst awaiting the results of laboratory investigations. See Aciclovir for dosing. There is no place for oral Acyclovir in neonatal treatment of acute HSV.

Contact precautions: either in single room or isolette for the duration of IV therapy unless advised earlier by Infection Control/Clinical Microbiologist. Refer to Infection Prevention Manual – Standard and Transmission Based Precautions. These neonates continue to excrete HSV for some days. A review of all the latest culture/PCR results should be done before taking of isolation.

One year mortality has reduced to 29% for disseminated disease and 14% for CNS disease with introduction of high dose acyclovir therapy, while neurological complications among survivors at 12 months of age are 25% and 70% in disseminated and CNS disease respectively.

Long Term Oral Suppressive Therapy after Acute Treatment

Long term oral suppressive therapy is currently recommended; as better neurodevelopmental outcome and fewer cutaneous recurrences have been reported. Discuss with a Clinical Microbiologist regarding duration of therapy; 6 months is recommended. Monitor for adverse effects.

Follow Up

Infants with neonatal HSV infection should be followed up and evaluated for recurrent disease and neurological sequelae.

Management of Infant with Presentation Compatible with HSV

Obtain virological specimens as detailed above, including CSF, and commence treatment with IV Aciclovir (high dose), see NCCU Medication Protocol Aciclovir.

Contact precautions: either in single room or isolette for the duration of IV antiviral therapy. Isolation may need to be prolonged beyond this period pending results of virological investigations. Refer to Infection Prevention Manual – Standard and Transmission Based Precautions.

Length of treatment will be determined by extent of disease. Suggested duration of treatment for confirmed neonatal HSV infection is 14 days for infants with SEM disease and 21 days for CNS and disseminated disease. If there are CSF abnormalities, repeat CSF examination towards the end of the treatment should be performed. Neonates with positive HSV on repeat CSF need further anti-viral treatment and have poor prognosis. Consultation with Clinical Microbiologist is advised.
**HSV INFECTIONS IN PREGNANCY: NEONATAL MANAGEMENT**

(Australasian Society for Infectious diseases 2014)

### Asymptomatic infant with low risk of neonatal HSV disease
- i.e. mother with recurrent genital infection, or primary genital or systemic infection seroconverted well prior to delivery with or without genital lesions at delivery

### Asymptomatic infant with high risk of neonatal HSV disease
- i.e. mother with primary genital or systemic infection close to delivery or infant born through birth canal with active HSV disease to mother with no prior history of genital HSV

### Newborn develops symptoms or signs of HSV disease
- Vesicular skin lesions or atypical pustular or bullous lesions, especially on presenting part (note: may be absent)
- Seizures
- Unexplained sepsis with -ve blood cultures not responding to antibiotics
- Low platelets
- Elevated LFTs
- DIC (disseminated intravascular coagulation)
- Respiratory distress (after day 1 of life)
- Corneal ulcer/keratitis

### Newborn develops symptoms of clinical disease while monitored or surface swab grows/ detects HSV (i.e. laboratory confirmed infection)
- As transmission is rare in this setting, most experts follow infants for clinical disease and educate family about signs of infection if no genital lesions. However, if genital lesions present then swabs (eye, throat, umbilicus, rectum +/- urine) and blood for HSV PCR at 24 hours of life or beyond to detect asymptomatic infection. Note: swabs taken <24 hours are thought to indicate colonisation not infection.

### Performance:
- LP (CSF analysis, viral culture, HSV PCR)
- FBP
- LFT’s
- HSV PCR on blood
- Surface swabs, eye, throat, umbilicus, rectum, urine (if not collected already), skin vesicle.

### Commence IV aciclovir immediately from birth (suspected HSV disease), duration will depend on surface culture & CSF results

### ACICLOVIR TREATMENT see Medication Guideline

**Duration:** The duration should always be discussed with microbiologist. For laboratory confirmed infection or clinical disease confined to skin, eye, mouth: the duration of therapy is generally 10-14 days. For encephalitis disseminated disease, 21 days is usually recommended. Pre-emptive therapy (high risk asymptomatic infant without laboratory confirmed infection): 10 days is recommended by experts.

### HSV CSF PCR positive: repeat LP and HSV PCR towards end of treatment to confirm clearance of viral DNA. If HSV PCR remains positive, extend treatment duration or consider alternate antiviral agent e.g. Foscarnet.

### All cases of laboratory confirmed infection. Survivors should be monitored closely for recurrences, eye disease, hearing impairment and neurological sequelae
**Herpes Simplex Virus (HSV): management of neonates born to HSV positive women**

### Related CAHS internal policies, procedures and guidelines

- **Standard and Transmission Based Precautions**
- **Aciclovir**

### References and related external legislation, policies, and guidelines

**WNHS: Infection Prevention Manual**
- **Neonatal Viral Infections**
- **Transmission Based Precautions**

Herpes Simplex Virus (HSV): management of neonates born to HSV positive women

This document can be made available in alternative formats on request for a person with a disability.

<table>
<thead>
<tr>
<th>File Path:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Document Owner:</td>
<td>Neonatology</td>
</tr>
<tr>
<td>Reviewer / Team:</td>
<td>Neonatal Coordinating Group; Infectious Diseases; Microbiology</td>
</tr>
<tr>
<td>Date First Issued:</td>
<td>February 2012</td>
</tr>
<tr>
<td>Last Reviewed:</td>
<td>25 August 2020</td>
</tr>
<tr>
<td>Amendment Dates:</td>
<td></td>
</tr>
<tr>
<td>Next Review Date:</td>
<td>August 2023</td>
</tr>
<tr>
<td>Approved by:</td>
<td>Neonatal Coordinating Group</td>
</tr>
<tr>
<td>Date:</td>
<td></td>
</tr>
<tr>
<td>Endorsed by:</td>
<td>Neonatal Coordinating Group</td>
</tr>
<tr>
<td>Date:</td>
<td></td>
</tr>
</tbody>
</table>

**Standards Applicable:**
- NSQHS Standards: [icons]
- Child Safe Standards: 1, 10

**Printed or personally saved electronic copies of this document are considered uncontrolled**